MedTrace Logo

A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

NCT06158516 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-12-06

No results posted yet for this study

Summary

pNENs still have a risk of recurrence after radical resection, and the overall recurrence and metastasis rate is as high as 13.7%-36.2% in China. At present, there is no standard adjuvant therapy for pNEN, and prospective studies are still lacking. This study was a randomized, double-blind, placebo-controlled, multicenter clinical trial to explore the efficacy and safety of surufatinib in the adjuvant treatment of pNET, in order to further improve the prognosis of patients and to provide high-quality research evidence for adjuvant therapy.

Conditions

  • Pancreatic Neuroendocrine Tumor

Interventions

DRUG

Surufatinib

Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle

DRUG

Placebo

Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Gang Jin, Doctor · Changhai Hospital

  • Jianming Xu, Doctor · Chinese PLA General Hosptial

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-30
Primary Completion
2026-11-29
Completion
2026-11-29

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06158516 on ClinicalTrials.gov